Literature DB >> 9464540

Interferon-induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK).

M Mandal1, D Bandyopadhyay, T M Goepfert, R Kumar.   

Abstract

To understand the mechanism of interferon (IFN)-mediated suppression of cell cycle progression, we have earlier shown that IFN-alpha enhances the expression of underphosphorylated retinoblastoma protein by inhibiting the cyclin-dependent kinase-2 (CDK-2) activity (Kumar and Atlas, Proc. Natl. Acad. Sci. 89, 6599-6603, 1992; Zhang and Kumar, Biochem. Biophysi. Res. Comm., 200, 522-528, 1994). In the studies presented here, we investigated the mechanism of inhibition of CDKs in IFN-treated cells by delineating the potential role(s) of CDK-inhibitors (CKIs) and CDK-activating kinase (CAK). We report that IFN-alpha inhibits the H-1 kinase activity associated with CDK-4 or CDK-2 due to induction of expression of CDK-inhibitor p21WAF1 (but not p27Kip1) as its immunodepletion from IFN-treated extracts restored the CDK-associated H-1 kinase activity. In addition, we also show that IFN-gamma induces expression of CDK-inhibitors p21WAF1 and p27Kip1 and inhibited the H-1 kinase activity associated with CDK-2 or CDK-4. The observed IFN-gamma-mediated inhibition of CDK-2 and CDK-4 kinase activity was due to enhanced interactions with p21WAF1 and p27Kip1, respectively. We also demonstrated that IFN-induced CKIs prevent CAK from activating the CDK-2 as immunodepletion of induced CKIs from the inhibitory extracts resulted in the restoration of CAK-mediated activation of CDK-2.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9464540     DOI: 10.1038/sj.onc.1201529

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  31 in total

1.  Long non-coding RNA slincRAD functions in methylation regulation during the early stage of mouse adipogenesis.

Authors:  Fan Yi; Pei Zhang; Yao Wang; Yin Xu; Zhengxi Zhang; Weizhi Ma; Bo Xu; Qing Xia; Quan Du
Journal:  RNA Biol       Date:  2019-06-19       Impact factor: 4.652

2.  IFN-γ +874 T/A polymorphisms contributes to cervical cancer susceptibility: a meta-analysis.

Authors:  Nannan Liu; Yan Song; Weifeng Shi
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  USP18 (UBP43) Abrogates p21-Mediated Inhibition of HIV-1.

Authors:  Edmund Osei Kuffour; Kerstin Schott; Ananda Ayyappan Jaguva Vasudevan; Jessica Holler; Wolfgang A Schulz; Philipp A Lang; Karl S Lang; Baek Kim; Dieter Häussinger; Renate König; Carsten Münk
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

4.  Interferon gamma +874 T/A polymorphism contributes to cancer susceptibility: a meta-analysis based on 17 case-control studies.

Authors:  Yuan-Yuan Mi; Qian-Qian Yu; Bin Xu; Li-Feng Zhang; Zhi-Chao Min; Li-Xin Hua; Ning-Han Feng; Yong Yao
Journal:  Mol Biol Rep       Date:  2010-12-03       Impact factor: 2.316

5.  Diabetic LDL inhibits cell-cycle progression via STAT5B and p21(waf).

Authors:  Maria Felice Brizzi; Patrizia Dentelli; Marzia Pavan; Arturo Rosso; Roberto Gambino; Maria Grazia De Cesaris; Giovanni Garbarino; Giovanni Camussi; Gianfranco Pagano; Luigi Pegoraro
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

6.  Antiproliferative activity of monastrol in human adenocarcinoma (MCF-7) and non-tumor (HB4a) breast cells.

Authors:  Lilian Areal Marques; Simone Cristine Semprebon; Andressa Megumi Niwa; Gláucia Fernanda Rocha D'Epiro; Daniele Sartori; Ângelo de Fátima; Lúcia Regina Ribeiro; Mário Sérgio Mantovani
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-03       Impact factor: 3.000

Review 7.  Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity.

Authors:  Elise Alspach; Danielle M Lussier; Robert D Schreiber
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-03-01       Impact factor: 10.005

Review 8.  p21 in cancer: intricate networks and multiple activities.

Authors:  Tarek Abbas; Anindya Dutta
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

9.  The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties.

Authors:  Jitka Holcakova; Peter Tomasec; Joachim J Bugert; Eddie Cy Wang; Gavin Wg Wilkinson; Roman Hrstka; Vladimir Krystof; Miroslav Strnad; Borivoj Vojtesek
Journal:  Antivir Chem Chemother       Date:  2010-01-05

10.  Effects of concurrent use of rh-IFN-gamma and curcumin on the anti-proliferative capacity of HL-60 cells.

Authors:  Y Wu; Y Chen; W Chen
Journal:  J Tongji Med Univ       Date:  1999
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.